Article Link: FDA Approves New Indication for Gilotrif (afatinib) in EGFR Mutation-Positive NSCLC Ridgefield, Conn., January 16, 2018 – B...
FDA Approves Lynparza (olaparib tablets) for Germline BRCA-Mutated Metastatic Breast Cancer
Article Link: FDA Approves Lynparza (olaparib tablets) for Germline BRCA-Mutated Metastatic Breast Cancer January 12, 2018 — The U....
GSK Receives FDA Approval for Expanded Indication for Fluarix Quadrivalent (Influenza Vaccine) for Persons 6 Months and Older
Article Link: GSK Receives FDA Approval for Expanded Indication for Fluarix Quadrivalent (Influenza Vaccine) for Persons 6 Months and Older ...
FDA Approves Xgeva (denosumab) for the Prevention of Skeletal-Related Events in Patients with Multiple Myeloma
Article Link: FDA Approves Xgeva (denosumab) for the Prevention of Skeletal-Related Events in Patients with Multiple Myeloma THOUSAND OAK...
Bausch + Lomb Receives FDA Approval of Lumify (brimonidine tartrate) Over-the-Counter Eye Drop for the Treatment of Eye Redness
Article Link: Bausch + Lomb Receives FDA Approval of Lumify (brimonidine tartrate) Over-the-Counter Eye Drop for the Treatment of Eye Redness &#...
FDA Approves Segluromet (ertugliflozin and metformin hydrochloride) for Type 2 Diabetes
Article Link: FDA Approves Segluromet (ertugliflozin and metformin hydrochloride) for Type 2 Diabetes KENILWORTH, N.J. & NEW YORKR...
FDA Approves Steglujan (ertugliflozin and sitagliptin) for Type 2 Diabetes
Article Link: FDA Approves Steglujan (ertugliflozin and sitagliptin) for Type 2 Diabetes KENILWORTH, N.J. & NEW YORK–(BUSINESS ...
FDA Approves Steglatro (ertugliflozin) for Type 2 Diabetes
Article Link: FDA Approves Steglatro (ertugliflozin) for Type 2 Diabetes KENILWORTH, N.J. & NEW YORK–(BUSINESS WIRE) December 2...
FDA Updates the Label of Tasigna to Reflect that Certain Patients with a Type of Leukemia May be Eligible to Stop Treatment After Sustained Response
Article Link: FDA Updates the Label of Tasigna to Reflect that Certain Patients with a Type of Leukemia May be Eligible to Stop Treatment After Sustai...
FDA Approves Giapreza (angiotensin II) to Treat Dangerously Low Blood Pressure
Article Link: FDA Approves Giapreza (angiotensin II) to Treat Dangerously Low Blood Pressure December 21, 2017 — The U.S. Food and ...
